Introduction
Modification of the amino acidr esidues serine and threonine by adding or removing O-GlcNAch as emerged as ac ritical post-translational modification that has ad ynamic impact on multiple biological processes. [1] This form of glycosylation, which consists of as ingle N-acetylglucosamine (GlcNAc) linked to serine or threonine residues,o ccurs primarily in nuclear and cytoplasmic proteins. [2] Thea ddition and removal of O-GlcNAc from serine or threonine residues is ar eversiblep rocess catalyzed by just two enzymes:O -GlcNAc transferase (OGT) and OGlcNAcase (OGA). [3] OGT catalyzes the transfer of GlcNAc from ah igh-energyd onor substrate (UDP-GlcNAc), which is an end product of the hexosamine biosynthetic pathway (HBP), providing al ink to glucose metabolism, and serving as the basis for defining O-GlcNAc as ag lucoses ensor. [4] OGA in turn hydrolyzes O-GlcNAc from protein carriersa nd,t ogether with OGT,d ynamically regulates the cycling of O-GlcNAc. [3] Protein stabilization and transcriptionalr egulation are among other functional roles identified for theO -GlcNAcm odification in addition to nutrient sensing. [5, 6] It has been shown that O-GlcNAc can competew ith and/or allosterically regulate phosphorylation in multiple proteins and that the crosstalk between OGlcNAc andp hosphorylation is ac omplexg lobal system in which both post-translational modifications regulate each other and generate av ast array of chemical diversity amongst substrates. [7] Aberrant O-GlcNAc modifications have been implicated in the pathologyo fm etabolic [8, 9] and neurodegeneratived iseases, [10] [11] [12] as well as in cancers [13] [14] [15] and autoimmunity. [16] Therefore, reliable methodsf or O-GlcNAcm onitoring and manipulation are in constant demand. [17] Although severala nti-OGlcNAc antibodies have provenu seful in biological experiments,t hey are biased towardp articular carrierp roteins. Different anti-O-GlcNAc antibodies often show distinct detection profiles for the same specimens. [18, 19] Ac omplementary method to antibody-based glycan detection is chemoenzymatic glycan labeling, which exploits unnatural nucleotide sugar donors equippedw ith ab ioorthogonal chemical tag and glycosyltransferases to directly label specific glycan acceptor substrates. [20] This strategy has been used to detect Fuca(1-2)Gal, [21] N-acetyllactosamine( LacNAc), [22] core 1a nd 2O -glycans, [23] and af ew other higher order glycans. [20] Coincidentally, O-GlcNAcylation was originally discovered through ac hemoenzymatic approacht hat exploited b1-4 galactosyltransferase( GalT1) to incorporate radiolabeled [
[2] Subsequent refinement of this methoda nd the development of a GalT1 mutant (Y289L) with donor promiscuity enabled the incorporation of ac hemical tag to the donor substrate to replace the radioactivel abel. [24, 25] This strategy has been extensively used to introduce variousc hemicalt ags to probe OGlcNAc biology in cell lysates ford ownstream applications such as immunoblotting, proteomics, [26, 27] as well as cellular imaging. [28] However, O-GlcNAcd etection in histological specimens has barely been explored. Despite the discovery that aberrant O-GlcNAcylation is associated with multiple disease states,l ittle is known about the distribution of OGlcNAca cross different organs and tissues. To date, no comModification of nuclear and cytoplasmic proteins by the addition or removal of O-GlcNAcd ynamically impactsm ultiple biological processes. Here, we presentt he development of ac hemoenzymatic histology method for the detection of O-GlcNAc in tissue specimens. We appliedt his methodt os creen murine organs,u ncovering specific O-GlcNAc distribution patterns in differentt issue structures. We then utilized our histology methodf or O-GlcNAc detection in human brain specimens from healthy donors and donors with Alzheimer's disease and found higherl evels of O-GlcNAci ns pecimensf rom healthy donors. Wea lso performed an analysisu sing am ultiple cancer tissue array,u ncovering different O-GlcNAcl evelsb etween healthya nd cancerous tissues, as well as different O-GlcNAc cellulard istributionsw ithin certain tissue specimens. This chemoenzymatic histology method therefore holds great potential for revealing the biology of O-GlcNAci np hysiopathological processes.
prehensive histological study of O-GlcNAc has been reported. [29, 30] Previously,t he Wu laboratory adapted chemoenzymatic LacNAc labeling to detect changes in LacNAc expression in tissue specimens, am ethod termed chemoenzymatic histology of membrane polysaccharides (CHoMP). [22, 31] Here, we expanded the scopeofC HoMP for the detection of O-GlcNAc in tissue samples by using GalT1 (Y289L) and highlight the powero f this new method through the analysiso fO -GlcNAcg lycosylation patterns in murine tissues and human clinicals pecimens.
Results and Discussion
GalT1 (Y289L) is known to accept unnaturalU DP-GalNAc analogues, including donors bearing ketone and azide groups.I t has been shown that alkyne substrates coupled to ac helating azide probe through ligand-assisted copper-catalyzed azidealkyne cycloaddition (CuAAC) can increasethe labeling efficiency up to 38-foldc ompared to the reaction with azide donors in flow cytometry experiments.
[32] Therefore, we first assessed whether this enzyme could also accept an alkyne-bearing donor analogue. We chose BTTP,aligand developed in our lab, for CuAAC because it has been shown to dramatically accelerate the rate of this reactionb yc oordination with the Cu I generated in situ. [33, 34] Using a-crystallin, an O-GlcNAc-bearing protein purified from bovine eye lens, we found that GalT1 (Y289L) could indeed accept the alkyne-tagged donor UDP-Npentynylgalactosamine (UDP-GalNAl). However,w hen compared side-by-side with UDP-N-azidoacetylgalactosamine (UDPGalNAz)i nw estern blot analyses, GalT1 (Y289L) showedh igher activity towardt he azide donor ( Figure S1 in the Supporting Information). Nevertheless, ac ombination of UDP-GalNAl and the accelerated biotin azide was found to afford ahigher labeling signal in histological specimens ( Figure 1B )i nw hich neutravidin-HRP and tyramides ignal amplification (TSA) were used for signal amplification. [31] The better labeling afforded by this protocols uggestst hat the high efficiency of the click reaction in the complex tissue environment might have compensated for the lower enzyme activity in the initial step.
We further confirmed that GalT1 (Y289L) hasu nusualr eaction conditions for tissue labelingc ompared with most glycosylation enzymes. Although most glycosyltransferases exhibited optimal activity at 37 8C, GalT1 (Y289L) preferred lower temperatures in histological specimens (e.g.,48C; Figure S2 ). Furthermore, GalT1 (Y289L) on tissue sections required minimal concentrations ( % 10-20 mgmL À1 )f or optimal activity,a nd the reactione fficiency surprisingly decreased with increasing concentrations( Figure S3 ), presumablyd ue to self-inactivation. Donorc oncentration ( Figure S4 ) and incubation time (Figure S5 ) behaved normally,w ith increased labeling correlating with longer reactiont imes or higherc oncentrationso fd onor until the signal reached ap lateau.G alT1 (Y289L) was previously reportedt op ossess nonspecific activity towardt he acceptor substrate, accepting terminal N-acetylglucosamine residues in N-glycans. [35] Cell fractionation or pretreatment with PNGaseF to removeN -glycans is often employed to enhance specificity. [36] In histological specimens, pre-treatment with PNGaseF can also abolishN -glycans ignals ( Figure S6 ). In tissues pretreated withP NGaseF,t he highest signal intensity for O-GlcNAc labeling by GalT1 (Y289L) colocalized with DAPI nuclear stain ( Figure 1C ). The schematic representation of our optimized method for detection of O-GlcNAci nt issue sections is shown in Figure 1A . With an optimized protocol in hand, we proceeded to screen murine tissue specimensf or O-GlcNAcd istribution patterns. Although the cellular distribution of O-GlcNAc has been extensively studied in cell cultures and tissue homogenates, little is knowna bout tissue distribution of O-GlcNAc, apart from the relative abundance of RNA transcripts encoding OGlcNAc cycling enzymes (NCBI publicd atabase). [1] Using our OGlcNAc chemoenzymatic histology analysis, we succeeded in determining the distributiono fO -GlcNAci nm ouse tissues including kidney,b rain, and intestine (Figure 2) , as well as in lung, stomach, testis, spleen, heart, skin, and pancreas (Figure S7) . Most organs exhibited distinct patterns of O-GlcNAc expression in different tissue structures, and even within different cellular compartments. For example, duct cells in kidney showedt he highestO -GlcNAc expression ( Figure 2A) , with the signal mostly localized to the nuclei. By contrast, very low levels of O-GlcNAc were observed in the glomeruli, the cluster of capillaries where waste products are filtered from the blood. In the intestine, most cells in the villi showedi ntense OGlcNAc labeling,b ut the crypts located at the base of the villi, housingi ntestinals tem cells and niche cells, showed remarkably little staining ( Figure 2B ). In brain sections, we observed the highest O-GlcNAc expression localized to the hippocampus ( Figure 2C ), the elongated ridges on the floor of each lateral ventricle of the brain thought to be the center of emotion, memory,a nd the autonomic nervous system, which is consistent with ap reviouso bservation by antibody-based immunohistochemistry (IHC). [29] Notably,t he resolution achieved by our chemoenzymatic histology methodi ss ignificantly highert han that afforded by IHC. In lung sections, the cells in the alveoli showed significant O-GlcNAc staining, but little was observed in the bronchioles. In the testis, the seminiferous tubules staineds trongly,w hereas ducts in the epididymis showeda pattern of intercalating cellsw ith high levels of O-GlcNAc. In the pancreas, most cells contained little O-GlcNAc; however, the Islets of Langerhans stained strongly.H air follicles contained alternating cellsw ith high levels of O-GlcNAc.Alow OGlcNAcs ignal was detectedi nm urines pleen and stomach ( Figure S7 ).
Having confirmed that distinct O-GlcNAc expression patterns could be characterized in murine tissue samples by using our chemoenzymatic histology method,w ei nvestigated whether this approach could be used to analyzeh uman clinicals amples. We chose brain samples as the first targets for our analysis. It hasb een observed that O-GlcNAc within the brain is present on hundreds of proteins, including tau and the amyloid precursor protein, which are involved in the pathophysiology of Alzheimer's disease. [10] We obtainedb rain tissue sections from healthy donors andf rom donors with Alzheimer's disease (HarvardB rain Tissue Resource Center) and applied our chemoenzymatic histology method to examineO -GlcNAc expression. The difference in O-GlcNAc labeling was striking, clearly showingh igherl evels of O-GlcNAcl abeling in healthy brain specimens versus brain specimens from patients with Alzheimer's disease in Brodmanna reas 7a nd 24, as well as in the upper pons, but not on the cerebellum ( Figures 3a nd S8 , n = 3). Our observation is consistentw ith previous studies that reported an overall decrease in O-GlcNAcylation in the brains of patients with Alzheimer's disease by immunostaining of brain lysates, immunoprecipitation, [12] and IHC. [11] This experiment also nicely confirmed the utility of our chemoenzymatic histological method in clinical settings.
Multiple studies have provided evidence that aberrant levels of O-GlcNAc exist in breast, [37, 38] colon, [39] andp rostate cancer. [40] As asecond application, we appliedchemoenzymatic histology analysis of O-GlcNAct oac ommercialt issue array containing normal and cancerous specimens from 12 different organs to examine the differences in O-GlcNAc expression. We observed pronounced differences between healthya nd tumor specimens in most organs,p articularly in thyroid, testis, and lung tissues. The key findings from our tumor array screening are shown in Figure 4 .
It has been suggested that hyperproliferation of thyroid cancer cells might be related to an overall increasei nOGlcNAcl evels. [41] Consistent with this hypothesis, we observed qualitatively highers tainingi nt he cancerous tissue (papillary carcinoma) compared to the normal thyroid tissue ( Figure 4A ), which was confirmed by the quantification of mean fluorescence intensity (MFI) of the full tissue specimens and coverage area percentageo fO -GlcNAcs ignal ( Figure S9) . Interestingly,i n the healthy tissue, O-GlcNAc staining wasl ocated primarilyi n the nucleus, whereas adiffuse cytoplasmic signal was observed for cancerous specimens. In testis,w eobserved that spermatocytes in the healthy tissue showed significant O-GlcNAc staining. By contrast, very little signal limited to af ew scattered cells was detected in the spermatocytic seminoma specimen (Figures 4B andS 8) . We refrainedf rom drawing population-wide conclusions from a single tissue specimen observation;h owever,m ost reports of aberrant O-GlcNAcylation in cancer have described increased levels of this post-translationalm odification linked to tumor hyperproliferation, the decrease in O-GlcNAc signal in seminoma might suggest ad ifferent proliferation mechanism. [42, 43] Althoughh ealthy lung tissue showedl ittle O-GlcNAc staining, the lung squamous cell carcinoma sample showed as ignificant signal increase. Similar to what was observed for the thyroid cancer specimen, we detectedacytoplasmic staining pattern in the cancerous tissue ( Figures 4C and S9) . The observed higherO -GlcNAc staining levels with chemoenzymatic histology analysis were in agreement with ar eport observing an overall increase in O-GlcNAc expression in lung cancer. [39] Amongo ther organsi ncludedi nt he array,p rostate, colon, bladder,a nd larynx also showed increased O-GlcNAcs taining in cancerous tissues compared to normals pecimens. No significant differencesweredetected between tumor and normal tissues in tongue, lymph node, pancreas, and muscles pecimens. The healthy breast core contained little ductal tissue to establish ar elevant comparison ( Figure S9 ).
Conclusions
In this work, we developed am ethod for the detection of OGlcNAci nh istological specimens based on chemoenzymatic glycan labeling.V aluable and integral information regarding the distribution of O-GlcNAcw ithin organs andc ell compartmentsc an be obtained by using this strategy.B ya nalyzing murinet issue sections, we uncovered patternso fd ifferential O-GlcNAcd istribution associated with tissue structures such as the hypothalamus in the brain, the glomeruli in the kidney,o r the crypts in the intestine. We further appliedt his chemoenzymatic histology methodt oa nalyze human brain samples from healthyd onors and donors with Alzheimer's disease. Higher levels of O-GlcNAc were detected in specimensf rom healthy donorb rains in agreement with published observations. [10] We then analyzed am ultiple cancert issue array discovering different O-GlcNAcl evels between healthy and canceroust issues, in addition to different O-GlcNAc cellular distribution for some specimen pairs. Our results suggest possible aberrant OGlcNAc in spermatocytic seminoma, af orm of cancert hat has not yet been studied in the context of O-GlcNAcylation.
We are aware that no population-wide conclusions can be drawn from observations made from such al imited sample size. However,o ur results clearlyd emonstrated that chemoen- www.chembiochem.org zymaticg lycan labeling can be applied to tumor biopsies to provide valuablei nformation regarding distribution patternso f O-GlcNAcw ithin tissue structures and cell compartments, as well as changes in O-GlcNAcl evels during tumor development. As we previously reported for LacNAc-bearing glycans,c hemoenzymatic histology analysisc an generate quantitative information of glycan expression for tissue arrays with large sample sizes. Population-wide changes or possible trends relatedt o tumor grade or stage can be discovered from such analysis. [31] Significantly,t he efficacy and utility of chemoenzymatic histology for such applications has been validated by mass-spectrometry-based glycomicsanalysis. 38 
Experimental Section
General methods and materials:A ll reagents and solvents were acquired from Fisher Scientific and were used as received unless otherwise stated. Electrophoresis and western blotting were performed by using Bio-Rad equipment. Primary antibodies were obtained from various sources:O -GlcNAc antibody from Biolegend, GAPDH antibody from R&D Systems, and PARP antibody from TACS. a-Crystallin was purchased from Sigma-Aldrich. Photomicrographs were acquired on aB Z-X700 Keyence Microscope, and all images were processed by using ImageJ software. Statistical analysis and graph generation was completed by using GraphPad Prism 7s oftware. Human brain tissue specimens were obtained from the Harvard Brain Tissue Resource Center.T he human tissue array MC245a was purchased from US Biomax.
Mice:A ll animal studies were carried out under ap rotocol approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute. C57BL/6 mice were bred and housed in the vivarium of The Scripps Research Institute, and were euthanized at 6-8 weeks and immediately perfused with 4% formalin. Organs were harvested and immediately immersed in zinc formalin fixative for 24 h. Tissues were paraffine mbedded by the TSRI Histology Core Facility and sectioned on amicrotome at 5 mm.
Chemoenzymatic histology:S ections were deparaffinizeda nd rehydrated according to standard protocols. Specifically,t he slides were sequentially immersed in coplin jars for 5min in 40 mL of: Histo-Clear II (National Diagnostics) twice, ethanol twice, 70 % aqueous ethanol twice, 50 %a queous ethanol twice and dH 2 O once. Ah ydrophobic barrier was drawn around the tissue samples on the slides with aP AP pen. Tissues were immersed in TBS + 0.1 % Tween-20 (TBST,5 0mL) for 10 min. Slides were then placed in a humidified chamber,a nd PNGaseF NEB standard reaction solution (100 mL) was added (1 G1 buffer,1%N P-40, and 2 mLP NGaseF). Slides were incubated overnight at 37 8C, followed by TBST wash (3 5min). Slides were placed again in ah umidified chamber,a nd the enzyme solution was added. The enzyme solution contained GalT1 (25 mgmL À1 ), UDP-GalNAl (500 mm), MnCl 2 (1 mm), NaCl (50 mm), HEPES (20 mm), NP-40 (2 %), pH 7.9. The slides were incubated for 3h at 4 8C. The slides were then washed with TBST (3 5min). The slides were returned to ah umidified chamber and blocked with avidin/biotin. Avidin solution (1 drop;B iolegend kit) was added to the tissue, and the slides were incubated at room temperature for 10 min, followed by TBST wash (3 3min each). Biotin solution (1 drop) was then added to the tissue, and the slides were incubated at room temperature for 10 min, followed by TBST wash (3 3min each). The slides were placed again in ah umidified chamber and "clicked" to ab iotin probe with as olution containing accelerated azide-biotin probe (50 mm), [32] CuSO 4 (75 mm), BTTP ligand (150 mm), sodium ascorbate (2.5 mm)i nT BST for 1h at room temperature. Following three washes in TBST (5 min each), the tissues were blocked for 10 min in 0.3 %h ydrogen peroxide diluted in TBS at room temperature and then washed with TBST (3 5min) to remove the H 2 O 2 .T he slides were placed in ah umidified chamber and incubated with neutravidin-HRP (1:100 in TBST) for 1hat room temperature, then subsequently washed with TBST (3 5min). The slides were placed in ah umidified chamber and incubated with TSA-Plus FITC reagent, according to the manufacturer's protocol (1:50 dilution for 5min at room temperature, protected from light), then washed with TBST (3 5min) and mounted with Prolong anti-fade gold with Dapi (Invitrogen).
Image processing:A ll tissues were prepared with an egative control (same treatment without GalT1) in serial sections. Images were acquired at the maximum microscope gain to achieve 80 %s ignal saturation with am onochrome camera, and negative controls were acquired with the same acquisition parameters. By using Image J, minimum intensity was increased until signal was undetectable in negative controls, and this value was established as background and subtracted from each positive image. Pseudo RGB color was assigned to each channel, usually Green for O-GlcNAc and blue for nuclear DAPI stain. Each specimen pair in the tumor array (healthy and cancerous specimens from the same organ) were processed with the same parameters. MFI quantification was performed for the full tissue selection, and the percentage coverage area was determined by automatic particle selection after threshold setting (80/255) and comparison to the total tissue area.
Immunoblotting:I nv itro test reactions were performed as described in the ThermoFisher O-GlcNAc Click-It kit with a-crystallin (50 mL). In short, a-crystallin (20 mg) was labeled overnight at 4 8C in ar eaction solution (20 mL) containing MnCl 2 (7.5 mm), UDPGalNAz (25 mm), GalT1 (1 mg), NaCl (50 mm), HEPES (20 mm, pH 7.9), and NP-40 (2 %). The crude mixture was further diluted to 50 mLi nareaction solution containing accelerated azide-biotin probe (50 mm), [32] premixed CuSO 4 (75 mm)a nd BTTP ligand (150 mm), and sodium ascorbate (2.5 mm). The reaction mixture was shaken for 1h at room temperature, and the crude mixture was directly loaded and run in 4-12 %B is·Tris gels (Novex) with MES running buffer for 1.5 ha t1 00 V. Gels were then transferred by using Novex Blotting buffer onto nitrocellulose membranes at 300 mA for 2h.Membranes were blocked for 1hat room temperature by using 5% powdered nonfat milk in TBST and subsequently incubated overnight with anti-biotin-HRP antibody (1:5000 in 5% milk-TBST) at 4 8Cw ith shaking. Membranes were then washed 3 5min with TBST and SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher) for 3min and subjected to X-ray exposure.
